Miraculins Inc (Miraculins) is a research and development company engaged in the discovery and validation of cancer biomarkers, which enable the development of diagnostic tools and therapeutic products. The company focuses on biomarker discovery using its proprietary B.E.S.T Platform for the screening and identification of target proteins and peptides related to diseases. The B.E.S.T. Platform technology utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery. The company's research and development programs include P2V, PSP94, and F/T PSA for prostate cancer; MIR-GP1 suite of markers for gastric cancer and MIR-CC1 for colorectal cancer. Miraculins entered into an agreement with Inverness Medical Innovations, Inc., a developer of consumer medical diagnostic products, for the development and commercialization of Miraculins’ preeclampsia technology. Miraculins is headquartered in Manitoba, Canada.
Miraculins Inc. Key Recent Developments
Dec 08, 2011: Miraculins Appoints William Roberts To Board
Dec 21, 2011: Miraculins Successfully Passes Critical ISO 13485 Certification Audit
Dec 23, 2011: Miraculins Appoints Dr Milan Gupta To PreVu Medical Advisory Board
Dec 23, 2011: Miraculins Names James Kinley As CFO
Jan 12, 2012: Alere Maintains Exclusive Option To License Miraculins
This comprehensive SWOT profile of Miraculins Inc. provides you with an in-depth strategic analysis of the company's businesses and operations. The profile will give you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of the 'Profile on Demand' Service, covering over 50,000 of the world's leading companies. Once purchased, We will comprehensively research and author a full strategic analysis of Miraculins Inc. and deliver this direct to you in pdf format within two business days (excluding weekends).
The profile contains critical company information including*,
- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Introduction
GlobalData's clinical trial report, “Psoriasis Global Clinical Trials Review, H1, 2012" provides data on the Psoriasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Psoriasis. It includes an overview of the tri ... more
Promethean Corp. (Promethean) is a New York based Health Care company. The company develops, manufactures and distributes its own products and is also involved in providing various health care services. The company through its wholly owned subsidiary, Ceres Living, produces and sells the AI ... more
Introduction
GlobalData’s new report, “Austria Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others” provides key market data on the Austria Neurology Devices market. The report provides value (USD mill ... more
As drug makers continue to jostle for market share and deal with declining revenues from their off-patent blockbuster drugs, M&A activity is showing no indication of slowing down in 2013. Pfizer is not leaving any stone unturned as the company continues its growth. Less than two months afte ... more
US demand for influenza vaccines will remain high in the coming decade, following a post-flu pandemic spike, predicts business intelligence provider GlobalData.
According to the company’s latest epidemiology report, seasonal influenza vaccine demand will increase from the 142 million expect ... more
Biotech companies are exploring alternative options to supplement their in-house research and development (R&D), abandoning the traditional blockbuster drug model to instead pursue deals and buy their way to success, says healthcare intelligence providers GlobalData in a new report, which e ... more